FI3525828T3 - Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja - Google Patents

Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja Download PDF

Info

Publication number
FI3525828T3
FI3525828T3 FIEP17784700.1T FI17784700T FI3525828T3 FI 3525828 T3 FI3525828 T3 FI 3525828T3 FI 17784700 T FI17784700 T FI 17784700T FI 3525828 T3 FI3525828 T3 FI 3525828T3
Authority
FI
Finland
Prior art keywords
antibody
drug conjugate
antigen
binding fragment
drug
Prior art date
Application number
FIEP17784700.1T
Other languages
English (en)
Inventor
Andrea Therese Hooper
Kimberly Ann Marquette
Chakrapani Subramanyam
Hans-Peter Gerber
Chad Michael May
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of FI3525828T3 publication Critical patent/FI3525828T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (23)

Patenttivaatimukset
1. Vasta-aine-ladke-konjugaatti, mihin sisältyy: (a) vasta-aine tai sen antigeeniä sitova fragmentti, joka sitoutuu fibronektiinin ylimääräiseen domeeniin B, jolloin vasta-aine tai antigeeniä sitova fragmentti käsittää raskasketjun vaihtelevan alueen, joka käsittää kolme CDR:ää, jotka sisältävät SEO ID NO:t: 3, 5 ja 7, ja kevytketjun vaihtelevan alueen, joka käsittää kolme CDR:ää, jotka sisältävät SEO ID NO:t: 12, 13 ja 14, jolloin raskasketju sisältää muokatun kysteiinitähteen kohdassa 290 (K290C), EU- indeksin Kabat-numeroinnin mukaisesti, ja jolloin kevytketju käsittää muokatun kysteiinitähteen kohdassa 183 (kK183C), Kabat-numeroinnin mukaisesti, (b) linkkeri ja (c) lääke.
2. Patenttivaatimuksen 1 mukainen vasta-aine-lääke-konjugaatti, jolloin vasta-aine, tai antigeeniä sitova fragmentti, sisältää raskasketjun vaihtelevan alueen, johon sisältyy SEQ ID NO: 1 tai 21, ja kevytketjun vaihtelevan alueen, johon sisältyy SEO ID NO: 10.
3. —Patenttivaatimuksen 1 tai 2 mukainen vasta-aine-lääke-konjugaatti, jolloin vasta- aine, tai antigeeniä sitova fragmentti, sisältää raskasketjun, johon sisältyy SEO ID NO: 19 tai 25, ja kevytketjun, johon sisältyy SEO ID NO: 31.
4. — Jonkin patenttivaatimuksen 1 - 3 mukainen vasta-aine-lääke-konjugaatti, jolloin vasta-aine, tai antigeeniä sitova fragmentti, sisältää raskasketjun vaihtelevan alueen, johon sisältyy mutaatio lysiinistä arginiiniksi kohdassa 94 (K94R), Kabat- numeroinnin mukaisesti.
5. — Jonkin patenttivaatimuksen 1 - 4 mukainen vasta-aine-lääke-konjugaatti, jolloin linkkeri on pilkkoutuva linkkeri.
6. — Jonkin patenttivaatimuksen 1 - 5 mukainen vasta-aine-lääke-konjugaatti, jolloin linkkeri on valittu ryhmästä, jonka muodostavat
O 9 O O O / 4 or (X JANA, 0 Ho i NH N7 ANS eX diS i 5 O NZ s.00000 SÅS diS-C20CO ja x O 0 OA H H MEH DT ov HO X J a —NH 0” NH Aclys-vc å ? .
7. — Jonkin patenttivaatimuksen 1-5 mukainen vasta-aine-lääke-konjugaatti, jolloin linkkeriin konjugoituna vasta-aineeseen, tai sen antigeeniä sitovaan fragmenttiin, ja lääkkeeseen sisältyy seuraava rakenne: O O : 0 4 o OY NÅN Ny 0 H 6 Y NH ANH,
8. — Jonkin patenttivaatimuksen 1 - 7 mukainen vasta-aine-lääke-konjugaatti, jolloin lääkeaine on sytotoksinen aine.
9. Jonkin patenttivaatimuksen 1 - 8 mukainen vasta-aine-lääke-konjugaatti, jolloin lääke on auristatiini.
10. Patenttivaatimuksen 9 mukainen vasta-aine-lääke-konjugaatti, jolloin auristatiini on valittu ryhmästä, jonka muodostavat H o H N, N N < YK ro O O © Os © N N SN 0101 \—/ , H o N SY AN N vw, Oo Äl o_o i N N O H - 1569 SI ; and o ON o oy NL : N N / N NH, SN o N O > f N OT N = 9411 KS? ja H © N Po N A N N O A | Ow O SH i N N O H = SI 4574
11. Patenttivaatimuksen 9 mukainen vasta-aine-lääke-konjugaatti, jolloin auristatiini on 0101, ja jolloin linkkeriin konjugoituun auristatiiniin sisältyy seuraava rakenne: HETI TO
O O. O O. O N N SN \—/ 12 Jonkin patenttivaatimuksen 1-11 mukainen vasta-aine-lääke-konjugaatti käsittäen raskasketjun vaihtelevan alueen, johon sisältyy SEO ID NO: 21, ja kevytketjun vaihtelevan alueen, johon sisältyy SEO ID NO: 10, vc-linkkeri ja auristatiini 0101.
13. Jonkin patenttivaatimuksen 1-11 mukainen vasta-aine-lääke-konjugaatti, jolloin raskasketjuun sisältyy SEO ID NO: 25 ja kevytketjuun sisältyy SEO ID NO: 31, vc- linkkeri ja auristatiini 0101.
14. Jonkin patenttivaatimuksen 1-3 tai 5-11 mukainen vasta-aine-lääke-konjugaatti, johon sisältyy raskasketju, johon sisältyy SEO ID NO: 19, ja kevytketju, johon sisältyy SEQ ID NO: 31, vc-linkkeri ja auristatiini 0101.
15. Jonkin patenttivaatimuksen 1-14 mukainen vasta-aine-lääke-konjugaatti, jolloin sytotoksinen aine, linkkeri ja vasta-aine tai sen antigeeniä sitova fragmentti ovat liitetty luomaan rakenne: o H ? H 0 J XA, LAWN X, 0 o O N (ON ALASKAA N OT ja KY TY AO 0 H 6 X \—/ NH OP NH, missä: X-S edustaa vasta-ainetta, tai sen antigeeniä sitovaa fragmenttia, jolloin S on vasta- aineessa, tai sen antigeeniä sitovassa fragmentissa, oleva vähintään yhden kysteiinitähteen rikkiatomi.
16. Jonkin patenttivaatimuksen 1 - 14 mukainen vasta-aine-lääke-konjugaatti, johon sisältyy (a) vasta-aine, tai sen antigeeniä sitova fragmentti, joka sitoutuu fibronektiinin ylimääräiseen domeeniin B, jolloin vasta-aineeseen, tai antigeeniä sitovaan 5 fragmenttiin, sisältyy raskasketju, johon sisältyy SEO ID NO: 25, ja kevytketju, johon sisältyy SEO ID NO: 31; (b) pilkkoutuva linkkeri ja (c) sytotoksinen lääke, jolloin pilkkoutuva linkkeri, sytotoksinen lääke ja vasta-aine tai sen antigeeniä sitova fragmentti ovat liitetty luomaan rakenne: o H O H d H KEN > > OSIN Ly 07 NH, missä: X-S edustaa vasta-ainetta, tai sen antigeeniä sitovaa fragmenttia, ja S on vasta- aineessa tai sen antigeeniä sitovassa fragmentissa oleva vähintään yhden kysteiinitähteen rikkiatomi.
17. Farmaseuttinen koostumus, mikä sisältää jonkin patenttivaatimuksen 1 - 16 mukaista vasta-aine-lääke-konjugaattia ja farmaseuttisesti hyväksyttävää kantaja- ainetta.
18. Koostumus, mikä sisältää useita jonkin patenttivaatimuksen 1 - 16 mukaisia vasta- aine-lääke-konjugaatteja ja valinnaisesti farmaseuttista kantaja-ainetta, jolloin koostumuksen keskimääräinen DAR on välillä 3 - 5 tai 1 - 3.
19. Jonkin patenttivaatimuksen 1 - 16 mukaisen vasta-aineen raskasketjua ja kevytketjua koodaava nukleiinihappo, tai sen antigeeniä sitova fragmentti, tai vektori käsittäen nukleiinihapon tai isäntäsolu käsittäen nukleiinihapon tai vektorin.
20. Prosessi jonkin patenttivaatimuksen 1 - 16 mukaisen vasta-aine-lääke-konjugaatin tuottamiseksi, sisältäen: (a) yhdistetään linkkeri lääkkeeseen:; (b) konjugoidaan linkkeri ja lääke vasta-aineeseen, tai sen antigeeniä sitovaan fragmenttiin, ja (c) puhdistetaan vasta-aine-lääke-konjugaatti, jolloin konjugointi on paikkaspesifinen vasta-aineen, tai sen antigeeniä sitovan fragmentin, yhdelle tai useammalle muokatulle kysteiinitähteelle.
21 Jonkin patenttivaatimuksen 1 - 16 mukainen vasta-aine-lääke-konjugaatti käytettäväksi EDB+FN -ekspressiohäiriön tai -sairauden hoitoon subjektissa.
22. Vasta-aine-lääke-konjugaatti käytettäväksi patenttivaatimuksen 21 mukaisesti, jolloin EDB+FN -ekspressiohäiriö tai -sairaus on syöpä.
23. Vasta-aine-lääke-konjugaatti käytettäväksi patenttivaatimuksen 22 mukaisesti, jolloin syöpä on ei-pienisoluinen keuhkosyöpä, paksusuolensyöpä, haimasyöpä, lymfooma ja rintasyöpä.
FIEP17784700.1T 2016-10-17 2017-10-03 Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja FI3525828T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662409081P 2016-10-17 2016-10-17
PCT/IB2017/056093 WO2018073680A1 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Publications (1)

Publication Number Publication Date
FI3525828T3 true FI3525828T3 (fi) 2025-01-27

Family

ID=60117722

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17784700.1T FI3525828T3 (fi) 2016-10-17 2017-10-03 Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja

Country Status (22)

Country Link
US (5) US20190269791A1 (fi)
EP (3) EP4635516A3 (fi)
JP (4) JP7039577B2 (fi)
KR (1) KR102338660B1 (fi)
CN (2) CN110087691B (fi)
AU (3) AU2017344440B2 (fi)
CA (1) CA3040423A1 (fi)
DK (1) DK3525828T3 (fi)
ES (1) ES3007557T3 (fi)
FI (1) FI3525828T3 (fi)
HR (1) HRP20250056T1 (fi)
HU (1) HUE070615T2 (fi)
IL (2) IL310865A (fi)
LT (1) LT3525828T (fi)
MX (2) MX2019004434A (fi)
PL (1) PL3525828T3 (fi)
PT (1) PT3525828T (fi)
RS (1) RS66524B1 (fi)
RU (1) RU2758632C2 (fi)
SG (1) SG11201903400WA (fi)
SI (1) SI3525828T1 (fi)
WO (1) WO2018073680A1 (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US12478686B2 (en) * 2018-12-12 2025-11-25 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
US20240252662A1 (en) * 2021-05-20 2024-08-01 Case Western Reserve University Peptide drug conjugates specific to fibronectin isotypes for cancer therapy
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
CN121311252A (zh) * 2023-07-10 2026-01-09 上海药明合联生物技术有限公司 抗体药物偶联物及其生产
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025208105A1 (en) * 2024-03-29 2025-10-02 Pyxis Oncology, Inc. Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1997026885A1 (en) 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
AU2001239470A1 (en) * 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
CA2445898A1 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
EP2174958A1 (en) 2002-03-11 2010-04-14 Philogen S.p.A. Antibodies derived from anti ed-b l19 and targeting tumor vasculature
BR0313043A (pt) * 2002-07-31 2005-06-14 Schering Ag Conjugados efetores, processo para sua produção e seu uso farmacêutico
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CA2607954A1 (en) * 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
JP5748392B2 (ja) 2005-10-05 2015-07-15 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 絹タンパク質
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
EP2015775B1 (en) * 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
TWI412367B (zh) * 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
WO2008120101A2 (en) 2007-04-02 2008-10-09 Philogen S.P.A. The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
EP2167541B1 (en) 2007-07-25 2012-12-19 Philogen S.p.A. The ed-a antigen of fibronectin is associated with the neovasculature of tumour metastases
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
ES3000111T3 (en) * 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
EP2461832B1 (en) 2009-08-05 2017-06-28 Philogen S.p.A. Targeting of bone marrow neovasculature
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
BR112013007160A2 (pt) 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
EP2953976B1 (en) * 2013-02-08 2021-03-24 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2014174105A1 (en) * 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
SG11201605437YA (en) 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
GB2538023A (en) 2014-02-03 2016-11-02 Philochem Ag Targeted drug conjugates
PT3134127T (pt) * 2014-04-25 2020-04-09 Rinat Neuroscience Corp Conjugados de anticorpo-fármaco com alta carga de fármaco
TWI727380B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
TWI812873B (zh) * 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段

Also Published As

Publication number Publication date
DK3525828T3 (da) 2025-02-17
JP7039577B2 (ja) 2022-03-22
JP2019534706A (ja) 2019-12-05
IL266112B1 (en) 2024-03-01
IL310865A (en) 2024-04-01
BR112019007760A2 (pt) 2019-09-03
AU2017344440A1 (en) 2019-05-02
RU2019111303A (ru) 2020-11-17
KR102338660B1 (ko) 2021-12-10
CA3040423A1 (en) 2018-04-26
JP7383682B2 (ja) 2023-11-20
EP3525828A1 (en) 2019-08-21
WO2018073680A1 (en) 2018-04-26
IL266112B2 (en) 2024-07-01
AU2017344440B2 (en) 2020-07-30
AU2020260375B2 (en) 2023-11-30
SI3525828T1 (sl) 2025-04-30
US20190269791A1 (en) 2019-09-05
JP2023184697A (ja) 2023-12-28
JP2022016581A (ja) 2022-01-21
PL3525828T3 (pl) 2025-03-31
US11833216B2 (en) 2023-12-05
MX2019004434A (es) 2019-09-26
RU2019111303A3 (fi) 2020-11-17
LT3525828T (lt) 2025-02-25
IL266112A (en) 2019-06-30
AU2024201216A1 (en) 2024-05-16
US20240156977A1 (en) 2024-05-16
KR20190069493A (ko) 2019-06-19
AU2020260375A1 (en) 2020-11-19
HUE070615T2 (hu) 2025-06-28
CN110087691A (zh) 2019-08-02
EP4617283A2 (en) 2025-09-17
US20230241235A1 (en) 2023-08-03
EP3525828B1 (en) 2024-12-25
RS66524B1 (sr) 2025-03-31
SG11201903400WA (en) 2019-05-30
JP2025175010A (ja) 2025-11-28
ES3007557T3 (en) 2025-03-20
HRP20250056T1 (hr) 2025-04-11
MX2024003463A (es) 2024-04-03
US20240261423A1 (en) 2024-08-08
CN110087691B (zh) 2023-02-03
US20240181071A1 (en) 2024-06-06
EP4635516A3 (en) 2026-05-06
RU2758632C2 (ru) 2021-11-01
PT3525828T (pt) 2025-01-29
CN116251196A (zh) 2023-06-13
EP4635516A2 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
FI3525828T3 (fi) Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja
JP2021532831A5 (fi)
ES2814227T3 (es) Anticuerpos anti-CD123 y conjugados de los mismos
JP2018509908A5 (fi)
RU2504553C2 (ru) Антитела к her
ES2701188T3 (es) Conjugados anticuerpo-fármaco e inmunotoxinas
JP2016531915A5 (fi)
RU2014120629A (ru) Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака
JP2013519375A5 (fi)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2019534706A5 (fi)
JP2016503295A5 (fi)
JP2017537620A5 (fi)
JP2014039548A5 (fi)
JP2017534256A5 (fi)
HRP20201176T1 (hr) Antitijela protiv cd73 i njihova upotreba
UA116874C2 (uk) Імунокон&#39;югат анти-мезотеліну
JP2019532056A5 (fi)
HRP20200032T1 (hr) Antitijelo lijek konjugati
RU2016117810A (ru) Конъюгаты белок-полимер-лекарственное средство
JP2014502955A5 (fi)
JP2015527319A5 (fi)
NZ797493A (en) Anti-fgfr2 antibodies and methods of use thereof
JP2017535246A5 (fi)
JP2014507138A5 (fi)